Vanguard Capital Management
AKBA icon

Vanguard Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Vanguard Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9M Buy
11,322,143
+155,433
+1% +$185K ﹤0.01% 2686
2026
Q1 		$15.5M Buy
+11,166,710
New +$15.3M ﹤0.01% 2485

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management's AKBA Position: Q2 2026 in Review

Vanguard Capital Management increased its Akebia Therapeutics (AKBA) stake by 1.4% in Q2 2026, buying an estimated $185K and bringing the position to 11,322,143 shares worth $12.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2686.

Vanguard Capital Management first reported a position in AKBA in Q1 2026 and has held it in 2 quarters since. The position peaked at $15.5M in Q1 2026. 169 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Vanguard Capital Management held 11,322,143 shares of Akebia Therapeutics worth $12.9M as of Q2 2026.
  • Vanguard Capital Management bought 155,433 Akebia Therapeutics shares in Q2 2026, an estimated $185K.
  • Akebia Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2686 holding.
  • Vanguard Capital Management first reported a position in Akebia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Akebia Therapeutics position peaked at $15.5M in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.